6241 Fistula and Pseudostoma Management Using Platelet Rich Plasma

Janice Wilson, RN, CWOCN, Asheville Specialty Hospital, Wound Care Coordinator, Asheville, NC, Karl Branch, RN, Asheville Specialty Hospital, Wound Care, Asheville, NC and Denise Fuston, LPN, Cornerstone Hospital of Tucson, Wound Care Coordinator, Tucson, AZ
Introduction:  Fistulas and their surrounding wounds create a double challenge to the wound care professional.  Before the fistula forms a pseudostoma, the goal is to close the fistula and the wound around the fistula.  If a pseudostoma develops, the goal is to close the wound around it so that the pseudostoma is manageable with a pouch until surgical closure.

Purpose:  This case series describes outcomes of two fistulas and two pseudostomas, and their wounds. Platelet-rich-plasma (PRP)* was used either in combination with or to move the wound toward closure before NPWT.

Results:  The two fistulas were treated with PRP in conjunction with gauze-based NPWT to decrease effluent, close the wound, and close the fistula.  Fistula and Wound 1: Area decreased 39.7% and volume decreased 47.6% in 7 days, effluent decreased from 300 to 50 ml/day.  Fistula and Wound 2: Volume decreased 20.3% and effluent decreased markedly in 3 days; patient hospitalized for 17 days. Upon return, both therapies restarted, in 19 days volume decreased 89% and effluent decreased from 200 to 5 ml.

The two psuedostomas were treated with PRP in the surrounding wound for 2-3 treatments over 7 days to move the wound toward closure as quickly as possible; pseudostomas were not treated with PRP. Wound 3: 3 treatments over 7 days - 50.7% volume reduction, visible difference in pictures.  Wound 4: 2 treatments over 10 days – decrease 29.9% area, 49.9% volume, photos show visible epithelial coverage of graft and decrease in depth.

Conclusion: This poster shows two fistulas that closed with PRP and gauze-based NPWT, and two wounds around pseudostomas that closed quickly with PRP, allowing management with short term NPWT then pouching.

*AutoloGel System, Cytomedix, Inc.